Novel monoclonal antibody therapy for SARS-CoV-2 northwesternu jclinicalinvest
The SARS-CoV-2 spike protein is the main antigen in all approved COVID-19 vaccines and is also the only target for monoclonal antibody therapies. Immune responses to other viral antigens are generated after SARS-CoV-2 infection, but their contribution to the antiviral response remains unclear. Here, we interrogate whether nucleocapsid-specific antibodies can improve protection against SARSCoV-2.
We show that mice that received nucleocapsid-specific sera or a nucleocapsid-specific monoclonal antibody exhibited enhanced control of SARS-CoV-2. Nucleocapsid-specific antibodies elicited NK-mediated antibodydependent cellular cytotoxicity against infected cells.
Vi har opsummeret denne nyhed, så du kan læse den hurtigt. Hvis du er interesseret i nyheden, kan du læse hele teksten her. Læs mere: